Dr. Doug Ethell is the founder and CEO of Leucadia Therapeutics, a pre-clinical stage company developing an early diagnostic for Alzheimer’s disease and a therapeutic device to stop the disorder at its earliest stage. Dr. Ethell received a Ph.D. in Neurobiology from The University of British Columbia in Vancouver, he was a Human Frontiers of Science Long Term Fellow at The Max Planck Institute for Psychiatry in Munich, Staff Scientist at The Scripps Research Institute and La Jolla Institute for Allergy & Immunology, and a faculty member at the University of California Riverside. In 2017, Dr. Ethell was Professor of Neuroscience, Chair of Graduate Faculty, and Head of Molecular Neurobiology at The Western Univ of Health Sciences before joining Leucadia Therapeutics full-time. He has published more than 85 peer-reviewed articles and presentation abstracts.